CLINICAL TRIAL | the abstract

Principal Investigator: Dr. Jennifer Cather

An open-label long-term safety study of Serlopitant for the treatment of pruritus (itch).

Chronic pruritus impacts quality of life. Participants 18 years and older were randomized to placebo or Serlopitant; patients rated their itch improvement over time.  The study completed on Jan 21, 2020, and results is scheduled to publish in late 2020.

SOTA Formula Consideration Based on Data:

CBD helps treat painful itch. 20% of people will experience chronic pain associated with inflammatory diseases, neuropathies, or medications such as chemotherapy at some point in their life and is a significant cause of suffering. Learn more about the benefits of SOTA Sleep Tincture and SOTA Rebound and Reclaim for relief from itching.

Study dates: 2018